• NIH awards T3D Therapeutics $9m to fund a trial of its lead product pharmaceutical-technology
    May 23, 2019
    US-based T3D Therapeutics has announced it has received a $9m grant over four years from the US National Institutes of Health (NIH)’s National Institute of Aging to support its Phase II clinical trial of its lead candidate T3D-959 in Alzheimer’s disease.
PharmaSources Customer Service